SteadyMed to Host an Analyst and Investor Reception
April 14, 2016 07:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., April 14, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a pre-NDA stage specialty pharmaceutical company focused on the development of drug products to treat orphan and...
SteadyMed Announces Initiation of Inter Partes Review Proceedings by U.S. Patent and Trademark Office Against a United Therapeutics Patent
April 11, 2016 07:00 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Provides Corporate Update and Reports Fourth Quarter and Full Year 2015 Financial Results
March 29, 2016 16:05 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., March 29, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed to Present at RBC Capital Markets 2016 Global Healthcare Conference
February 17, 2016 16:15 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Feb. 17, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a pre-NDA stage specialty pharmaceutical company focused on the development of drug products to treat orphan and...
SteadyMed to Present at 18th Annual BIO CEO & Investor Conference
February 02, 2016 16:15 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Feb. 02, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a pre-NDA stage specialty pharmaceutical company focused on the development of drug products to treat orphan and...
Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European Medicines Agency
January 06, 2016 08:00 ET
|
SteadyMed Therapeutics
VANCOUVER, British Columbia and SAN RAMON, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME), (TSX:COM) and SteadyMed Ltd. (Nasdaq:STDY), today announced that the...
SteadyMed Receives Orphan Drug Designation for Trevyent for the Treatment of Pulmonary Arterial Hypertension
January 05, 2016 07:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent Compared to Remodulin
December 07, 2015 07:00 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases...
SteadyMed Reports Recent Developments and Third Quarter 2015 Financial Results
November 12, 2015 16:05 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
SteadyMed to Report Recent Developments and Third Quarter 2015 Financial Results
November 05, 2015 07:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases...